Hanger Downgraded to Strong Sell - Analyst Blog

By
A A A

Zacks Investment Research downgraded Hanger Inc. ( HGR ) by a notch to a Zacks Rank #5 (Strong Sell) on Mar 13, 2014.

Why the Downgrade?

On Feb 12, this premier provider of orthotic and prosthetic (O&P) patient care services reported its results for 2013-fourth-quarter ended Dec 31, 2013. Hanger witnessed downward estimate revisions after posting flat year-over-year adjusted earnings per share of 54 cents for the fourth quarter. Earnings, however, beat the Zacks Consensus Estimate by a penny.

Revenues increased 3.2% to $278.2 million but lagged the Zacks Consensus Estimate of $284 million. The increase was driven by an $11.1 million increase in the Patient Care segment revenues, partially offset by a $2.5 million decline in the Products & Services segment revenues.

The decline in Products & Services revenues was attributable to the impact of the acquisitions made by this segment in 2012 and 2013 on Hanger's distribution business as well as a fall in demand for higher priced prosthetic devices from independent O&P practices.

Hanger's adjusted operating margin fell 120 basis points to 12.7% in the fourth quarter due to higher material costs and accounts receivable reserves related to operational issues experienced at a small non-clinic unit within the Patient Care segment.

As of Dec 31, 2013, Hanger's cash and cash equivalents stood at $9.9 million, considerably down from $19.2 million at the end of 2012.

For fiscal 2014, one estimate moved down in the past 30 days, with no upward revision in the same time frame, sinking the Zacks Consensus Estimate by 0.5% to $2.16 per share.

Moreover, Hanger continues to face macroeconomic headwinds like reimbursement uncertainties, sequestration and RAC audits, which are likely to reduce the bottom line going forward.

Other Stocks to Consider

Some better-ranked medical product stocks are Enzymotec Ltd. ( ENZY ), Covidien plc ( COV ) and Stryker Corp. ( SYK ). While Enzymotec sports a Zacks Rank #1 (Strong Buy), both Covidien and Stryker hold a Zacks Rank #2 (Buy).



COVIDIEN PLC (COV): Free Stock Analysis Report

ENZYMOTEC LTD (ENZY): Free Stock Analysis Report

HANGER ORTHOPED (HGR): Free Stock Analysis Report

STRYKER CORP (SYK): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: COV , ENZY , HGR , SYK

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

139,392,686
  • $5.41 ▼ 18.52%
108,086,733
  • $17.04 ▲ 1.61%
88,411,032
  • $42.085 ▼ 1.19%
35,897,863
  • $101.79 ▲ 0.21%
34,635,836
  • $46.68 ▲ 0.34%
31,162,075
  • $4.36 ▲ 12.37%
31,086,421
  • $26.21 ▲ 0.61%
30,930,862
  • $17.09 ▼ 2.95%
As of 9/18/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com